![Barbara Brunnhuber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barbara Brunnhuber
Amministratore Delegato presso Mireca Medicines GmbH
Profilo
Barbara Brunnhuber is the founder and currently serves as the Chief Executive Officer & Managing Director of Mireca Medicines GmbH, which she founded in 2017.
She also previously worked as the Head of Operations at to-BBB technologies BV.
Posizioni attive di Barbara Brunnhuber
Società | Posizione | Inizio |
---|---|---|
Mireca Medicines GmbH
![]() Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Amministratore Delegato | 01/03/2017 |
Precedenti posizioni note di Barbara Brunnhuber
Società | Posizione | Fine |
---|---|---|
to-BBB technologies BV
![]() to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
to-BBB technologies BV
![]() to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Mireca Medicines GmbH
![]() Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Health Technology |
- Borsa valori
- Insiders
- Barbara Brunnhuber